

Prostate Cancer – Pipeline Insight, 2020

<https://marketpublishers.com/r/P9606AFAED89EN.html>

Date: November 2020

Pages: 350

Price: US\$ 5,000.00 (Single User License)

ID: P9606AFAED89EN

Abstracts

This report can be delivered to the clients within 5 Business days

DelveInsight's, "Prostate Cancer – Pipeline Insight, 2020," report provides comprehensive insights about 900+ companies and 900+ pipeline drugs in Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Prostate Cancer Understanding

Prostate Cancer: Overview

The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S. About 1 in 9 men will be diagnosed with prostate cancer in their lifetime. This year, nearly 191,000 men will be diagnosed with prostate cancer. Growths in the prostate can be benign (not cancer) or malignant (cancer).

Benign growths (like benign prostatic hyperplasia (BPH):

Are rarely a threat to life

Don't invade the tissues around them

Don't spread to other parts of the body

Can be removed and can grow back very slowly (but usually don't grow back)

Malignant growths (prostate cancer):

May sometimes be a threat to life

Can spread to nearby organs and tissues (such as the bladder or rectum)

Can spread (metastasize) to other parts of the body (like lymph nodes or bone)

Often can be removed but sometimes grow back

Prostate cancer cells can spread by breaking away from a prostate tumor. They can travel through blood vessels or lymph nodes to reach other parts of the body. After spreading, cancer cells may attach to other tissues and grow to form new tumors, causing damage where they land.

Treatment

Primarily, surgery, radiation therapy, and proton beam therapy are the current treatment options of prostate cancer. However, chemotherapy, hormonal therapy, cryosurgery, and high intensity focused ultrasound (HIFU) are also belonging to the treatment strategies, depending on clinical conditions, and outcomes. Also, the choice of treatment depends on the stages of the disease progression, the level of prostate specific antigen (PSA), the Gleason score among others.

Prostate Cancer Emerging Drugs Chapters

This segment of the Prostate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Prostate Cancer Emerging Drugs

Relugolix: Myovant

Relugolix is the Myovant's lead product candidate and is an orally available small molecule, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. Relugolix is similar to the approved GnRH antagonist Firmagon (degarelix; Ferring/Astellas), as both drugs deplete androgen levels without an accompanying flare of testosterone that occurs with GnRH agonist treatment.

FP-001: Foresee Pharmaceuticals

FP-001 is a long-acting gonadotropin releasing hormone (GnRH) agonist being developed as Leuprolide Mesylate for Injectable Suspension. It is under development by Foresee Pharmaceuticals and ScinoPharm Joint Venture and is currently in Phase III stage for the treatment of Prostate Cancer. The drug candidate is being developed in different dosage formulations and depending on them, they are in different stages of development:-

LMIS 50 mg: Pre-registration stage (Foresee Pharmaceuticals submitted NDA for FDA approval of LMIS 50 mg)

LMIS 25 mg: Phase III Stage

LMIS 8.3 mg: Research Stage

GX301: Mediolanum

GX301 is being developed by Mediolanum for the treatment of Prostate cancer. It is currently in phase II stage of development.

TAS3681: Taiho Oncology

TAS3681, a pure AR antagonist, is specifically designed to address the unmet medical need in CRPC patients by combining known mechanisms of action with novel ones:

A selective AR antagonist suppressing transactivation of both wild-type and mutated (including F876L) cell lines and inhibiting AR translocation to the nucleus

Downregulating AR expression in prostate cancer cells in vitro and in vivo and effectively suppressing androgen independent AR transactivation by outlaw pathways

Driving AR downregulation of full-length androgen receptor (FL-AR) and AR splice variants (eg, AR-v7) in vitro and in vivo, and suppressing AR dependent and AR-v7 dependent cell growth

Further product details are provided in the report.....

Prostate Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Prostate Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Prostate Cancer

There are approx. 900+ key companies which are developing the therapies for Prostate Cancer. The companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include Myovant and others

Phases

DelveInsight's report covers around 900+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Prostate Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Prostate Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prostate Cancer drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Prostate Cancer.

A New Drug Application (NDA) has been submitted to the FDA for once-daily, oral relugolix (RRVT-601, Relumina) at a dose of 120 mg as treatment of male patients with advanced prostate cancer by the company.

Takeda has granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries) to relugolix (TAK-385). Takeda will retain commercial rights for relugolix in Asian countries, including Japan, where is actively conducting two phase 3 registration studies for the treatment of uterine fibroids.

March 2019: Foresee Pharmaceuticals announces submission of NDA for FDA approval of LMIS 50 mg

Prostate Cancer Report Insights

Prostate Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Prostate Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Prostate Cancer drugs?

How many Prostate Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prostate Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prostate Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Prostate Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AstraZeneca

Daiichi Sankyo

Abgenix

Orion Corporation

Pfizer

Bayer

Medivation LLC

Clovis Oncology

Laekna Limited

FutureChem

Foresee Pharmaceuticals

Mediolanum

Myovant

Taiho Oncology

Key Products

Capivasertib

PLX3397

ABX-EGF

ODM-201

Enzalutamide

BAY1841788

MDV3100

Rucaparib

LAE001

Ludotadipep

FP-001

GX301

Relugolix

TAS3681

Contents

Introduction

Executive Summary

Prostate Cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Prostate Cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Prostate Cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends

Prostate Cancer Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III and Preregistration)

Comparative Analysis

Relugolix: Myovant

Product Description

Research and Development

Product Development Activities

FP-001: Foresee Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

GX301: Mediolanum

Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
Comparative Analysis
TAS3681: Taiho Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Prostate Cancer Key Companies
Prostate Cancer Key Products
Prostate Cancer- Unmet Needs
Prostate Cancer- Market Drivers and Barriers
Prostate Cancer- Future Perspectives and Conclusion
Prostate Cancer Analyst Views
Prostate Cancer Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Prostate Cancer
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Prostate Cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Prostate Cancer – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/P9606AFAED89EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9606AFAED89EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970